share_log

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Thompson Craig B.

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Thompson Craig B.

再生元製藥公司 | 4:持股變動聲明-董事 Thompson Craig B.
美股SEC公告 ·  01/07 05:13

Moomoo AI 已提取核心訊息

On January 2, 2025, Thompson Craig B., associated with Regeneron Pharmaceuticals, acquired 166 shares of Common Stock at $0 per share through a grant or award. This transaction was reported as completed.Following the acquisition, Thompson Craig B.'s direct ownership of Regeneron's Common Stock increased to 620 shares. The shares were acquired under a 'Direct' ownership form, indicating personal ownership rather than through an intermediary or related entity.
On January 2, 2025, Thompson Craig B., associated with Regeneron Pharmaceuticals, acquired 166 shares of Common Stock at $0 per share through a grant or award. This transaction was reported as completed.Following the acquisition, Thompson Craig B.'s direct ownership of Regeneron's Common Stock increased to 620 shares. The shares were acquired under a 'Direct' ownership form, indicating personal ownership rather than through an intermediary or related entity.
在2025年1月2日,湯普森·克雷格與再生元製藥公司有關聯,獲得了166股普通股,價格爲每股0美元,通過贈與或獎勵完成。該交易已報告爲完成。收購後,湯普森·克雷格對再生元的普通股直接持有量增加至620股。這些股票是以'直接'所有權形式獲得的,表示個人所有權,而非通過中介或相關實體。
在2025年1月2日,湯普森·克雷格與再生元製藥公司有關聯,獲得了166股普通股,價格爲每股0美元,通過贈與或獎勵完成。該交易已報告爲完成。收購後,湯普森·克雷格對再生元的普通股直接持有量增加至620股。這些股票是以'直接'所有權形式獲得的,表示個人所有權,而非通過中介或相關實體。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息